{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:01:28Z","timestamp":1789664488933,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T00:00:00Z","timestamp":1521676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health","award":["RF-2011-02347694"],"award-info":[{"award-number":["RF-2011-02347694"]}]},{"name":"Fondazione Meyer ONLUS, Firenze, Italia"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.cca.2018.02.021","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T04:56:59Z","timestamp":1519189019000},"page":"25-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Functional and pharmacological evaluation of novel GLA variants in Fabry disease identifies six (two de novo ) causative mutations and two amenable variants to the chaperone DGJ"],"prefix":"10.1016","volume":"481","author":[{"given":"Lorenzo","family":"Ferri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duccio","family":"Malesci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Fioravanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Bagordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Filippini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ficcadenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1560-3907","authenticated-orcid":false,"given":"Raffaele","family":"Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Antuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Verrecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Mignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catia","family":"Cavicchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Guerrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2890-8179","authenticated-orcid":false,"given":"Amelia","family":"Morrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2018.02.021_bb0005","series-title":"The metabolic and Molecular Bases of Inherited Disease","first-page":"3733","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.cca.2018.02.021_bb0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.cca.2018.02.021_bb0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"issue":"2","key":"10.1016\/j.cca.2018.02.021_bb0020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ymgme.2014.11.004","article-title":"The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies","volume":"114","author":"Ferreira","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.cca.2018.02.021_bb0025","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1399-0004.2011.01689.x","article-title":"Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene","volume":"81","author":"Ferri","year":"2012","journal-title":"Clin. Genet."},{"issue":"3","key":"10.1016\/j.cca.2018.02.021_bb0030","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1096-7192(03)00136-7","article-title":"Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma","volume":"80","author":"Froissart","year":"2003","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.cca.2018.02.021_bb0035","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/humu.10275","article-title":"Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele","volume":"22","author":"Yasuda","year":"2003","journal-title":"Hum. Mutat."},{"issue":"11","key":"10.1016\/j.cca.2018.02.021_bb0040","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/ejhg.2011.87","article-title":"Fabry or not Fabry\u2013a question of ascertainment","volume":"19","author":"Houge","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.cca.2018.02.021_bb0045","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cge.12449","article-title":"Diagnostic dilemmas in Fabry disease: a case series study on GLA mutations of unknown clinical significance","volume":"88","author":"Smid","year":"2015","journal-title":"Clin. Genet."},{"issue":"1","key":"10.1016\/j.cca.2018.02.021_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","article-title":"A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance","volume":"51","author":"van der Tol","year":"2014","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.cca.2018.02.021_bb0055","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13023-016-0441-z","article-title":"Alpha-galactosidase A p.A143T, a non-Fabry disease-causing variant","volume":"11","author":"Lenders","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.cca.2018.02.021_bb0060","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijcard.2014.09.001","article-title":"Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance","volume":"177","author":"Smid","year":"2014","journal-title":"Int. J. Cardiol."},{"issue":"4","key":"10.1016\/j.cca.2018.02.021_bb0065","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.cca.2018.02.021_bb0070","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2018.02.021_bb0075","first-page":"S111","article-title":"Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies","volume":"47","author":"Germain","year":"2009","journal-title":"Gene"},{"key":"10.1016\/j.cca.2018.02.021_bb0080","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry disease with the pharmacological chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cca.2018.02.021_bb0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/mt.2009.220","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease","volume":"18","author":"Khanna","year":"2010","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.cca.2018.02.021_bb0090","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1096\/fj.04-2375com","article-title":"A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder","volume":"19","author":"Yam","year":"2005","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.cca.2018.02.021_bb0095","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines","volume":"32","author":"Benjamin","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"issue":"11","key":"10.1016\/j.cca.2018.02.021_bb0100","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/ejhg.2008.109","article-title":"Unbalanced GLA mRNAs ratio quantified by real-time PCR in Fabry patients' fibroblasts results in Fabry disease","volume":"16","author":"Filoni","year":"2008","journal-title":"Eur. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.cca.2018.02.021_bb0105","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1086\/339431","article-title":"Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype","volume":"70","author":"Ishii","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.cca.2018.02.021_bb0110","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.cca.2015.10.027","article-title":"Pitfalls in the detection of gross gene rearrangements using MLPA in Fabry disease","volume":"452","author":"Ferri","year":"2015","journal-title":"Clin. Chim. Acta"},{"issue":"2","key":"10.1016\/j.cca.2018.02.021_bb0115","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bbadis.2009.11.003","article-title":"Functional studies of new GLA gene mutations leading to conformational Fabry disease","volume":"1802","author":"Filoni","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"9","key":"10.1016\/j.cca.2018.02.021_bb0120","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/FPC.0b013e32830500f4","article-title":"Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone","volume":"18","author":"Shin","year":"2008","journal-title":"Pharmacogenet. Genomics"},{"issue":"1","key":"10.1016\/j.cca.2018.02.021_bb0125","first-page":"179","article-title":"The subcellular localization of soluble and membrane-bound lysosomal enzymes in I-cell fibroblasts: a comparative immunocytochemical study","volume":"39","author":"van Dongen","year":"1985","journal-title":"Eur. J. Cell Biol."},{"issue":"2","key":"10.1016\/j.cca.2018.02.021_bb0130","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human alpha-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J. Mol. Biol."},{"issue":"12","key":"10.1016\/j.cca.2018.02.021_bb0135","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.chembiol.2011.10.012","article-title":"The molecular basis of pharmacological chaperoning in human alpha-galactosidase","volume":"18","author":"Guce","year":"2011","journal-title":"Chem. Biol."},{"issue":"1","key":"10.1016\/j.cca.2018.02.021_bb0140","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.gene.2015.12.024","article-title":"Molecular and clinical studies in five index cases with novel mutations in the GLA gene","volume":"578","author":"Zizzo","year":"2016","journal-title":"Gene"},{"issue":"8","key":"10.1016\/j.cca.2018.02.021_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003632","article-title":"Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease","volume":"9","author":"Lukas","year":"2013","journal-title":"PLoS Genet."},{"issue":"5","key":"10.1016\/j.cca.2018.02.021_bb0155","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/1479-7364-2-5-297","article-title":"Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations","volume":"2","author":"Shabbeer","year":"2006","journal-title":"Hum. Genomics"},{"issue":"3","key":"10.1016\/j.cca.2018.02.021_bb0160","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF03401671","article-title":"Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes","volume":"3","author":"Eng","year":"1997","journal-title":"Mol. Med."},{"issue":"6","key":"10.1016\/j.cca.2018.02.021_bb0165","first-page":"1186","article-title":"Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease","volume":"53","author":"Eng","year":"1993","journal-title":"Am. J. Hum. Genet."},{"issue":"10","key":"10.1016\/j.cca.2018.02.021_bb0170","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/hmg\/3.10.1795","article-title":"Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene","volume":"3","author":"Eng","year":"1994","journal-title":"Hum. Mol. Genet."},{"issue":"8","key":"10.1016\/j.cca.2018.02.021_bb0175","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.ejhg.5201184","article-title":"Remarkable variability in renal disease in a large Slovenian family with Fabry disease","volume":"12","author":"Verovnik","year":"2004","journal-title":"Eur. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.cca.2018.02.021_bb0180","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.molmed.2011.10.003","article-title":"CFTR: folding, misfolding and correcting the DeltaF508 conformational defect","volume":"18","author":"Lukacs","year":"2012","journal-title":"Trends Mol. Med."},{"issue":"3\u20134","key":"10.1016\/j.cca.2018.02.021_bb0185","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cca.2011.10.023","article-title":"The use of high resolution melting analysis to detect Fabry mutations in heterozygous females via dry bloodspots","volume":"413","author":"Tai","year":"2012","journal-title":"Clin. Chim. Acta"},{"issue":"1","key":"10.1016\/j.cca.2018.02.021_bb0190","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1096-7192(02)00012-4","article-title":"Fabry disease: 45 novel mutations in the alpha-galactosidase A gene causing the classical phenotype","volume":"76","author":"Shabbeer","year":"2002","journal-title":"Mol. Genet. Metab."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898118300822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898118300822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T04:21:14Z","timestamp":1570767674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898118300822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":37,"alternative-id":["S0009898118300822"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2018.02.021","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional and pharmacological evaluation of novel GLA variants in Fabry disease identifies six (two de novo) causative mutations and two amenable variants to the chaperone DGJ","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2018.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}